StockNews.AI
ORN
StockNews.AI
2 hrs

80,802 Orion Corporation A shares converted into B shares

1. 80,802 A shares converted into B shares on September 19, 2025. 2. Total shares in Orion Corporation now stand at 141,134,278. 3. Company focuses on oncology and pain pharmaceuticals. 4. 2024 net sales reported at EUR 1,542 million. 5. Orion employs about 3,700 professionals globally.

3m saved
Insight
Article

FAQ

Why Neutral?

The share conversion is a standard corporate action with minimal direct market effects. Historical examples show similar conversions often lead to brief quiet periods in stock performance.

How important is it?

While the share conversion updates share classifications, it doesn't significantly influence Orion's marketability or performance.

Why No Impact?

Share conversions typically do not influence market sentiment or long-term trends. Historical patterns suggest minimal change in stock prices from such actions.

Related Companies

ABTPFEJNJ
September 19, 2025 02:00 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 19 SEPTEMBER 2025 at 9.00 EEST         80,802 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 80,802 A shares have been converted into 80,802 B shares. The conversion has been entered into the Trade Register on 19 September 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,890,981 A shares and 109,243,297 B shares. The number of votes of the company's shares is after the conversion 747,062,917. Orion Corporation Liisa HurmePresident and CEO    Mikko KemppainenGeneral Counsel   Contact person:Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721                                                  Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orionpharma.com Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News